BiotechTube

Tirzepatide + Placebo

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Obesity

Conditions

Obesity, Overweight, Metabolism and Nutrition Disorder

Trial Timeline

Sep 1, 2021 → Dec 27, 2022

NCT ID
NCT05024032

About Tirzepatide + Placebo

Tirzepatide + Placebo is a phase 3 stage product being developed by Eli Lilly for Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT05024032. Target conditions include Obesity, Overweight, Metabolism and Nutrition Disorder.

What happened to similar drugs?

20 of 20 similar drugs in Obesity were approved

Approved (20) Terminated (5) Active (0)
✅exenatide + PlaceboEli LillyApproved
✅TirzepatideEli LillyApproved
✅Micafungin + MicafunginAstellas PharmaApproved
✅MicafunginAstellas PharmaApproved
✅Zonegran + PlaceboEisaiApproved
✅lorcaserin hydrochloride XR + PlaceboEisaiApproved
✅Placebo + TirzepatideEli LillyApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT06962280Phase 3Active
NCT06914895Phase 3Active
NCT06191848ApprovedRecruiting
NCT06439277Phase 3Recruiting
NCT05708859ApprovedRecruiting
NCT06075667Phase 3Active
NCT06037252Phase 2Active
NCT06047548Phase 3Active
NCT05963022Phase 3Completed
NCT05536804Phase 2Active
NCT05696847Phase 1Completed
NCT05691712Phase 3Completed
NCT05556512Phase 3Active
NCT05412004Phase 3Completed
NCT05024032Phase 3Completed
NCT04235959Phase 1Completed
NCT04081337Phase 1Completed
NCT04050553Phase 1Completed
NCT04184622Phase 3Completed
NCT04166773Phase 2Completed

Competing Products

20 competing products in Obesity

See all competitors
ProductCompanyStageHype Score
MK0493MerckPhase 2
35
MK0557MerckPhase 3
40
AMG 786AmgenPhase 1
29
Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide PlaceboEli LillyPhase 2
39
TirzepatideEli LillyPhase 2
42
exenatide + PlaceboEli LillyApproved
43
BrenipatideEli LillyPhase 1
36
Orforglipron + PlaceboEli LillyPhase 3
47
TERN-601Terns PharmaceuticalsPhase 2
32
MBX 4291 + PlaceboMBX BiosciencesPhase 1
30
PG-102Rani TherapeuticsPhase 1
26
Orforglipron + PlaceboEli LillyPhase 1
29
Eloralintide + PlaceboEli LillyPhase 1
29
Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide PlaceboEli LillyPhase 2
27
LY3437943 + Midazolam + Warfarin + CaffeineEli LillyPhase 1
29
Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injectionSkye BiosciencePhase 2
29
TirzepatideEli LillyApproved
50
Adenosine + RegadenosonAstellas PharmaPre-clinical
26
Micafungin + MicafunginAstellas PharmaApproved
43
MicafunginAstellas PharmaApproved
43